Table I.
Trials with GLP-1 agonists.
| Drug | Trials | CVD outcome trial | Year of approbation | Route of administration |
|---|---|---|---|---|
| Exenatide (9) | DURATION | EXSCEL (QW) | 2005 FDA | Short action - subcutaneous injection b.i.d |
| 2006 EMA | Long action - once/week (QW) | |||
| Liraglutide (10) | LEAD | LEADER | 2009 EMA | Long action - Subcutaneous injection o.d. |
| 2010 FDA | ||||
| Albiglutide (11) | HARMONY | HARMONY OUTCOMES | 2014 FDA and EMA | Long action - Subcutaneous injection once/week |
| Dulaglutide (12) | REWIND | REWIND | 2014 | Long action - Subcutaneous injection once/week |
| Lixisenatide (13) | GETGOAL | ELIXA | 2016 | Short action - Subcutaneous injection o.d. |
| Semaglutide (14,15) | SUSTAIN 1,2 | 2017 | Long action - Subcutaneous injection once/week | |
| NCT01923181 | ||||
| NCT02461589 |